Treg Cell Therapeutics
Cord blood refers to the blood found in the umbilical cord and placenta, separated during childbirth. It is a precious source of life, containing abundant stem cells and various immune cells, making it valuable for the treatment of various intractable diseases.
Stem cells and immune cells contained in cord blood are purer, fresher, and more functional compared to those obtained from peripheral blood.
Cord blood could be used to family including siblings and parents, even with incompletely matched HLA. Notably, regulatory T cells from cord blood exhibit lower HLA expression compared to bone marrow or peripheral blood cells, enhancing the potential for allogeneic use.
Regulatory T cells (Tregs) constitute only 2-5% of total blood cells, playing a crucial role in maintaining immune tolerance and immune homeostasis within the body.
When the number or function of Tregs decreases, or when effector T cells become excessively activated, normal immune balance is disrupted. Such immune imbalances are observed in various autoimmune diseases.
IMMUNIQUE is developing universally applicable “off-the-shelf” therapeutics for various autoimmune diseases, including graft-versus-host disease (GvHD), aplastic anemia (AA), ankylosing spondylitis, and lupus.
Utilizing Chimeric Antigen Receptors (CAR) inserted into the surface of Treg cells, the CAR-Treg therapeutics target specific sites within organs or tissues.
Immunique aims to develop CAR-Treg therapeutics for a range of autoimmune diseases by integrating disease-specific scFv antibody fragments within the Immunique’s CAR-Platform.
